PPD Confirms Takeda’s NDA Submission Of Alogliptin And ACTOS(R) To U.S. FDA - Single Tablet For Diabetes Type 2
PPD, Inc. (Nasdaq: PPDI) today confirmed that Takeda Pharmaceutical Company Limited has submitted a new drug application to the U.S. Food and Drug Administration for marketing approval of alogliptin (SYR-322) and ACTOS® (pioglitazone HCl) in a single tablet for the treatment of type 2 diabetes. “We are very pleased with Takeda’s progression of the development of alogliptin/ACTOS,” said Fred Eshelman, PPD’s chief executive officer.
More: continued here